{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:37:42Z","timestamp":1761100662764,"version":"build-2065373602"},"reference-count":18,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2003,10,29]],"date-time":"2003-10-29T00:00:00Z","timestamp":1067385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2003,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The current study was conducted to analyze the long\u2010term results of autologous stem cell transplantation (ASCT) in patients with diffuse mantle cell lymphoma (MCL) in first disease remission.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Thirty\u2010three patients were treated. Thirty\u2010one patients had Ann Arbor Stage III or Stage IV disease. The hyper\u2010CVAD regimen (hyperfractionated intense\u2010dose cyclophosphamide, vincristine, continuous intravenous infusion of doxorubicin, and dexamethasone, alternating with high doses of cytarabine and methotrexate plus leucovorin rescue) was used for cytoreduction before ASCT. Patients were consolidated with high\u2010dose cyclophosphamide (120 mg\/kg), total body irradiation, and ASCT.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>At a median follow\u2010up of 49 months, the overall survival and disease\u2010free\u2010survival rates at 5 years were estimated to be 77% and 43%, respectively. Patients whose M. D. Anderson Lymphoma Tumor Score (TS) was \u2264 1 at the time of diagnosis or transplantation experienced longer disease\u2010free survival compared with those whose TS was &gt; 1 (<jats:italic>P<\/jats:italic> = 0.02). A \u03b2<jats:sub>2<\/jats:sub>\u2010microglobulin (\u03b2<jats:sub>2<\/jats:sub>m)level \u2264 3 mg\/L at the time of diagnosis or transplantation was also found to be strongly predictive of longer survival (5\u2010year survival rate of 100% vs. 22% in patients with a \u03b2<jats:sub>2<\/jats:sub>m level &gt; 3 mg\/L) (<jats:italic>P<\/jats:italic> = 0.0001).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>ASCT may prolong the overall survival in a subset of patients with MCL. This improvement has been observed for the most part in patients with low \u03b2<jats:sub>2<\/jats:sub>m levels (\u2264 3 mg\/L) and TS (\u2264 1). Randomized trials are required to fully assess the benefits of this strategy. Cancer 2003;98:2630\u20135. \u00a9 2003 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.11838","type":"journal-article","created":{"date-parts":[[2003,12,8]],"date-time":"2003-12-08T03:02:51Z","timestamp":1070852571000},"page":"2630-2635","source":"Crossref","is-referenced-by-count":75,"title":["Long\u2010term follow\u2010up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission"],"prefix":"10.1002","volume":"98","author":[{"given":"Issa F.","family":"Khouri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rima M.","family":"Saliba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace\u2010Julia","family":"Okoroji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra A.","family":"Acholonu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,12,4]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2780"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(00)00255-2"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3803"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009053541"},{"key":"e_1_2_5_6_2","first-page":"1860","article-title":"Report on the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone PP","year":"1971","journal-title":"Cancer Res"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/scd.1.1993.2.247"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058324"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008278605751"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.13"},{"key":"e_1_2_5_13_2","first-page":"482a","article-title":"Does transplantation improve outcome in mantle cell lymphoma (MCL)? A study from the EBMT","volume":"96","author":"Vanderberghe E","year":"2000","journal-title":"Blood"},{"key":"e_1_2_5_14_2","first-page":"13a","article-title":"High dose therapy and autologous hematopoietic transplantation for mantle cell lymphoma: the Stanford\/City of Hope experience","volume":"20","author":"Malone JN","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402406"},{"key":"e_1_2_5_16_2","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1182\/blood.V96.3.864","article-title":"Successful in vivo purging of CD34\u2010containing peripheral blood harvests in mantle cell lymphoma and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion","volume":"96","author":"Magni M","year":"2000","journal-title":"Blood"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.30143"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.9.3158"},{"key":"e_1_2_5_19_2","first-page":"726a","article-title":"Mantle cell lymphoma (MCL)\u2010 High rates of complete remission (CR) and prolonged failure\u2010free survival (FFS) with Rituxan\u2010hyperCVAD (R\u2010HCVAD) without stem cell transplant (SCT)","volume":"98","author":"Romaguera J","year":"2001","journal-title":"Blood"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.11838","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.11838","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T21:20:37Z","timestamp":1760304037000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.11838"}},"subtitle":["The prognostic value of \u03b2<sub>2<\/sub>\u2010microglobulin and the tumor score"],"short-title":[],"issued":{"date-parts":[[2003,12,4]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2003,12,15]]}},"alternative-id":["10.1002\/cncr.11838"],"URL":"https:\/\/doi.org\/10.1002\/cncr.11838","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2003,12,4]]}}}